Zura Bio Limited (ZURA)
NASDAQ: ZURA · Real-Time Price · USD
4.580
+0.110 (2.46%)
At close: Nov 8, 2024, 4:00 PM
4.570
-0.010 (-0.22%)
After-hours: Nov 8, 2024, 6:46 PM EST
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
The company is based in Henderson, Nevada.
Zura Bio Limited
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Robert Lisicki |
Contact Details
Address: 1489 W. Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 702-757-6133 |
| Website | zurabio.com |
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855644 |
| ISIN Number | KYG9TY5A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Lisicki | Chief Executive Officer and Director |
| Dr. Someit Sidhu M.D. | Founder and Director |
| Verender S. Badial | Chief Financial Officer |
| Kimberly Ann Davis | Chief Legal Officer and Corporate Secretary |
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Theresa Lowry | Chief Human Resources Officer |
| David Brady | Head of Business Development |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer and Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 8-K | Current Report |
| Sep 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 17, 2024 | EFFECT | Notice of Effectiveness |
| Sep 16, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Sep 13, 2024 | ARS | Filing |
| Sep 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |